^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Pancreatic Adenocarcinoma
    Drug:cisplatin (DNA synthesis inhibitor) +
    gemcitabine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The Panel recommends gemcitabine plus cisplatin for patients with metastatic or locally advanced disease, only for known BRCA1/2 mutations.